In this episode of "In the Interim," Don Berry shares the life and work of Jimmie Savage, his advisor and a legendary figure in Bayesian statistics.

Innovation in drug development requires perseverance, strategic thinking, and a shift in traditional practices to innovate clinical trials and improve drug development.

This week Dr. Michael Krams joins the podcast to discuss the art and slog of innovation in pharmaceutical companies and clinical trials.

In this compelling episode of "In the Interim," Dr. Mike Krams, a seasoned expert in clinical trials and drug development, joins us to discuss the art and slog of innovation in pharmaceutical companies.

We explore the history and modern complexities of ordinal outcomes in clinical trials, discussing their importance and the contentious debates surrounding their analysis.

In this latest episode of our podcast, Scott Berry discusses the controversial and vital topic of ordinal outcomes.